{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:01:19Z","timestamp":1781157679384,"version":"3.54.1"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>As a next-generation vaccine technology, mRNA vaccines mark a transformative advancement in vaccinology research. Their key strengths lie in rapid development cycles, high-efficiency manufacturing processes, robust immunogenic properties, and adaptable design frameworks. For infectious disease prevention, mRNA-based immunizations targeting SARS-CoV-2, such as the mRNA-1273 vaccine, have shown promising results in clinical evaluations. Validated efficacy metrics and safety profiles have supported their regulatory approval for public use. Additionally, mRNA platforms have shown substantial therapeutic potential against respiratory syncytial virus. However, this technology still faces multiple challenges, including poor stability, limited delivery efficiency, high production costs, unclear mechanisms of adverse reactions. Distinct from existing literature that primarily focuses on COVID-19 or specific delivery technologies, this review provides a comprehensive, integrated framework covering molecular design, delivery systems, and clinical translation across multiple viral pathogens, while also critically analyzing current controversies and future directions. This review aims to provide a comprehensive reference for researchers and clinicians in related fields.<\/jats:p>","DOI":"10.3389\/fmicb.2026.1821852","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:47:40Z","timestamp":1781156860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["mRNA vaccines against viral pathogens: molecular design, delivery systems, and clinical applications"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueke","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.omtn.2021.06.008","article-title":"Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA.","volume":"25","author":"Aldon","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes.","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine [clinical trial, phase III; journal article; multicenter study; randomized controlled trial; research support, N.I.H., extramural; research support, non-U.S. gov\u2019t].","volume":"384","author":"Baden","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses.","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","article-title":"Respiratory syncytial virus entry and how to block it.","volume":"17","author":"Battles","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity.","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1021\/acsnano.0c00326","article-title":"Big is beautiful: Enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer.","volume":"14","author":"Blakney","year":"2020","journal-title":"ACS Nano"},{"key":"B10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/1751-7915.13974","article-title":"mRNA vaccines against COVID-19: A showcase for the importance of microbial biotechnology.","volume":"15","author":"Br\u00fcssow","year":"2022","journal-title":"Microb. Biotechnol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"827256","DOI":"10.3389\/fimmu.2021.827256","article-title":"TLR7 signaling shapes and maintains antibody diversity upon virus-like particle immunization.","volume":"12","author":"Chang","year":"2022","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation.","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.abq7232","article-title":"First self-copying mRNA vaccine proves itself in pandemic trial.","volume":"376","author":"Cohen","year":"2022","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-642-38919-1_1","article-title":"Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease.","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans.","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","article-title":"Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses.","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1039\/c8tx00005k","article-title":"Correlation of the cytotoxic effects of cationic lipids with their headgroups.","volume":"7","author":"Cui","year":"2018","journal-title":"Toxicol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting.","volume":"384","author":"Dagan","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines.","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery.","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development.","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice.","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/QAI.0000000000000852","article-title":"Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: Results of a randomized, placebo-controlled clinical trial.","volume":"71","author":"Gandhi","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the advisory committee on immunization practices - United States, June 2021.","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41541-025-01166-1","article-title":"Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants.","volume":"10","author":"Gontu","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2001812","DOI":"10.1002\/adhm.202001812","article-title":"Next-generation vaccines: Nanoparticle-mediated DNA and mRNA delivery.","volume":"10","author":"Ho","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","article-title":"In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.","volume":"30","author":"Hoerr","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.cell.2023.04.024","article-title":"ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines.","volume":"186","author":"Hoffmann","year":"2023","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery.","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"B34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ymthe.2006.04.010","article-title":"RNA interference in vitro and in vivo using a novel chitosan\/siRNA nanoparticle system.","volume":"14","author":"Howard","year":"2006","journal-title":"Mol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19.","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine.","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","article-title":"Mechanism of action of mRNA-based vaccines.","volume":"16","author":"Iavarone","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"B38","doi-asserted-by":"publisher","first-page":"120431","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice.","volume":"266","author":"Islam","year":"2021","journal-title":"Biomaterials"},{"key":"B39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/QAI.0000000000000926","article-title":"Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: A randomized, double-blind, placebo-controlled clinical trial.","volume":"72","author":"Jacobson","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11882-023-01065-2","article-title":"mRNA COVID-19 vaccine anaphylaxis: Epidemiology, risk factors, and evaluation.","volume":"23","author":"Jaggers","year":"2023","journal-title":"Curr. Allergy Asthma Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/2051013613508729","article-title":"A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.","volume":"2","author":"Kallen","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1007\/s10973-021-10929-6","article-title":"Thermotropic effects of PEGylated lipids on the stability of HPPH-encapsulated lipid nanoparticles (LNP).","volume":"147","author":"Kalyanram","year":"2022","journal-title":"J. Therm. Anal. Calorim."},{"key":"B43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA.","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: Advances in technologies for therapeutic mRNA delivery.","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/0022-2836(87)90418-9","article-title":"At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells.","volume":"196","author":"Kozak","year":"1987","journal-title":"J. Mol. Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jama.2021.7215","article-title":"Rare PEG allergy triggered postvaccination anaphylaxis.","volume":"325","author":"Kuehn","year":"2021","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","article-title":"Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine.","volume":"156","author":"Kwon","year":"2018","journal-title":"Biomaterials"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1288879","DOI":"10.3389\/fimmu.2023.1288879","article-title":"An mRNA vaccine against rabies provides strong and durable protection in mice.","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response.","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics.","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"a5068","DOI":"10.1126\/sciadv.aba5068","article-title":"Development of a potent Zika virus vaccine using self-amplifying messenger RNA.","volume":"6","author":"Luisi","year":"2020","journal-title":"Sci. Adv."},{"key":"B52","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases.","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","article-title":"A critical analysis of codon optimization in human therapeutics.","volume":"20","author":"Mauro","year":"2014","journal-title":"Trends Mol. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ymthe.2021.01.030","article-title":"Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines.","volume":"29","author":"Moghimi","year":"2021","journal-title":"Mol. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3389\/fimmu.2020.02037","article-title":"The immune response and immunopathology of COVID-19.","volume":"11","author":"Mortaz","year":"2020","journal-title":"Front. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"110514","DOI":"10.1016\/j.celrep.2022.110514","article-title":"mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice.","volume":"38","author":"Mu","year":"2022","journal-title":"Cell Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e52445","DOI":"10.15252\/embr.202152445","article-title":"Linking transport and translation of mRNAs with endosomes and mitochondria.","volume":"22","author":"M\u00fcntjes","year":"2021","journal-title":"EMBO Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s40203-024-00244-x","article-title":"mRNA vaccine design for Epstein-Barr virus: An immunoinformatic approach.","volume":"12","author":"Oladipo","year":"2024","journal-title":"In Silico Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening.","volume":"27","author":"Orlandini Von Niessen","year":"2019","journal-title":"Mol. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021.","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology.","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology.","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA.","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1906128","DOI":"10.1002\/adma.201906128","article-title":"A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes.","volume":"32","author":"Ramishetti","year":"2020","journal-title":"Adv. Mater."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1038\/s41467-022-31005-z","article-title":"Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection.","volume":"13","author":"Rappaport","year":"2022","journal-title":"Nat. Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.18502\/ajmb.v14i1.8167","article-title":"New generation vaccines for COVID-19 based on peptide, viral vector, artificial antigen presenting cell, DNA or mRNA.","volume":"14","author":"Rezaei","year":"2022","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: Challenges and bottlenecks.","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"B69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: Current perspectives.","volume":"15","author":"Samaridou","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B70","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","article-title":"Human 5\u2019 UTR design and variant effect prediction from a massively parallel translation assay.","volume":"37","author":"Sample","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","article-title":"An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: A phase 2\/3 randomized trial [clinical trial, phase II; clinical trial, phase III; journal article; multicenter study; randomized controlled trial].","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies.","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.omtn.2022.04.036","article-title":"A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections.","volume":"28","author":"Schmidt","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B74","doi-asserted-by":"publisher","first-page":"eabo1827","DOI":"10.1126\/sciadv.abo1827","article-title":"Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses.","volume":"8","author":"Shi","year":"2022","journal-title":"Sci. Adv."},{"key":"B75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3390\/pharmaceutics14020460","article-title":"The potential of nanomedicine to unlock the limitless applications of mRNA.","volume":"14","author":"Taina-Gonz\u00e1lez","year":"2022","journal-title":"Pharmaceutics"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months [journal article; multicenter study; randomized controlled trial; research support, non-U.S. gov\u2019t].","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: The spike hypothesis.","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.chembiol.2023.09.015","article-title":"Highly efficient cellular expression of circular mRNA enables prolonged protein expression.","volume":"31","author":"Unti","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy.","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses.","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines.","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults.","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fncel.2017.00411","article-title":"Proteomic and metabolomic analyses of vanishing white matter mouse astrocytes reveal deregulation of ER functions.","volume":"11","author":"Wisse","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo.","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.3390\/ijms21186582","article-title":"mRNA vaccine era-mechanisms, drug platform and clinical prospection.","volume":"21","author":"Xu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2219870","DOI":"10.1080\/10717544.2023.2219870","article-title":"PEGylated pH-responsive peptide-mRNA nano self-assemblies enhance the pulmonary delivery efficiency and safety of aerosolized mRNA.","volume":"30","author":"Xu","year":"2023","journal-title":"Drug Deliv."},{"key":"B88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","article-title":"Non-viral vectors for RNA delivery.","volume":"342","author":"Yan","year":"2022","journal-title":"J. Control. Release"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e2202688","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies.","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e2004452","DOI":"10.1002\/adma.202004452","article-title":"Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo.","volume":"32","author":"Zeng","year":"2020","journal-title":"Adv. Mater."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","article-title":"A multiclade env\u2013gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.","volume":"27","author":"Zhang","year":"2021","journal-title":"Nat. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B93","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ymthe.2024.12.013","article-title":"Self-amplifying mRNA vaccines protect elderly BALB\/c mice against a lethal respiratory syncytial virus infection.","volume":"33","author":"Zuo","year":"2025","journal-title":"Mol. Ther."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1821852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:47:41Z","timestamp":1781156861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1821852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":93,"alternative-id":["10.3389\/fmicb.2026.1821852"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1821852","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1821852"}}